Foghorn Therapeutics Financials - Benzinga

Foghorn Therapeutics Inc

FHTXNASDAQ

Trade with Public

Trade with Public

$4.14

-0.06-1.43%

At close: Sep 17, 5:00 PM EST

$4.14

-0.06-1.43%

Pre-Market: 4:00 AM EST

Overview News Earnings Forecast Events Price TargetsFinancialsSentiment Ownership Compare Options Stock Report

Foghorn Therapeutics Financials

Foghorn Therapeutics (FHTX) financial statements — income, revenue, gross margin and key metrics.

Earnings & Guidance News

PRO
Foghorn Therapeutics Q2 EPS $(0.10) Beats $(0.23) Estimate, Sales $16.072M Beat $5.995M Estimate

Foghorn Therapeutics (NASDAQ:FHTX) reported quarterly losses of $(0.10) per share which beat the analyst consensus estimate of $(0.23) by 54.55 percent. This is a 64.29 percent increase over losses of $(0.28) per share

Benzinga Newsdesk

PRO
Foghorn Therapeutics Q1 EPS $(0.29), Inline, Sales $3.267M Miss $7.438M Estimate

Foghorn Therapeutics (NASDAQ:FHTX) reported quarterly losses of $(0.29) per share which met the analyst consensus estimate. This is a 3.33 percent increase over losses of $(0.30) per share from the same period last year.

Benzinga Newsdesk

PRO
Foghorn Therapeutics Q4 EPS $(0.34) Misses $(0.27) Estimate, Sales $9.247M Miss $9.500M Estimate

Benzinga Newsdesk

PRO
Foghorn Therapeutics Q3 EPS $(0.25) Beats $(0.30) Estimate, Sales $8.153M Beat $6.197M Estimate

Foghorn Therapeutics (NASDAQ:FHTX) reported quarterly losses of $(0.25) per share which beat the analyst consensus estimate of $(0.30) by 17.76 percent. This is a 19.35 percent increase over losses of $(0.31) per share

Benzinga Newsdesk

PRO
Foghorn Therapeutics Q2 EPS $(0.28) Beats $(0.33) Estimate, Sales $7.557M Beat $6.498M Estimate

Foghorn Therapeutics (NASDAQ:FHTX) reported quarterly losses of $(0.28) per share which beat the analyst consensus estimate of $(0.33) by 13.85 percent. This is a 37.78 percent increase over losses of $(0.45) per share

Benzinga Newsdesk

PRO
Foghorn Therapeutics Q1 EPS $(0.30) Beats $(0.31) Estimate, Sales $5.95M Beat $5.82M Estimate

Foghorn Therapeutics (NASDAQ:FHTX) reported quarterly losses of $(0.30) per share which beat the analyst consensus estimate of $(0.31) by 3.23 percent. This is a 49.15 percent increase over losses of $(0.59) per share

Benzinga Newsdesk